Dactolisib (BEZ235)

For research use only. Not for use in humans.

目录号：S1009 别名： NVP-BEZ235 中文名称：达克利司

CAS No. 915019-65-7

Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。在 3T3^TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Dactolisib可诱导自噬并抑制HIV-1的复制。Phase 2。

规格

价格

库存

购买数量

50mg	RMB 895.88	现货
100mg	RMB 1414.41	现货
200mg	RMB 2530.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dactolisib (BEZ235)发表文献407篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 35(1):108940

PubMed: 33784499 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5736

PubMed: 34086347 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2139

PubMed: 33946744 ( click the link to review the publication )

Cancers (Basel), 2021, 13(11)2778

PubMed: 34204960 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00254-3

PubMed: 34111400 ( click the link to review the publication )

Clin Sci (Lond), 2021, CS20210571

PubMed: 34282832 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:621906

PubMed: 34124031 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Int J Nanomedicine, 2021, 16:2173-2186

PubMed: 33758505 ( click the link to review the publication )
Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00805-X

PubMed: 34303705 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Neuroscience, 2021, S0306-4522(21)00070-1

PubMed: 33577953 ( click the link to review the publication )

SLAS Technol, 2021, 24726303211008858

PubMed: 33880947 ( click the link to review the publication )

J Burn Care Res, 2021, irz170

PubMed: 34213565 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Cell Rep, 2020, 32(12):108171

PubMed: 32966799 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E3058

PubMed: 33092134 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3689

PubMed: 33316942 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

J Mol Cell Biol, 2020, 12(8):644-653

PubMed: 31065693 ( click the link to review the publication )
Bioinformatics, 2020, btaa858

PubMed: 33067636 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12888

PubMed: 33338300 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9240

PubMed: 33287446 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.3432

PubMed: 32976685 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

Oncol Lett, 2020, 20(6):326

PubMed: 33123242 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )
Can J Physiol Pharmacol, 2020, 10.1139/cjpp-2020-0280

PubMed: 32893666 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29926

PubMed: 32654229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):524

PubMed: 32963283 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

Elife, 2020, 9:e53367

PubMed: 32513387 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-4245

PubMed: 32605911 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):223-235

PubMed: 31776938 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11487

PubMed: 32661241 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )
Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2019, 316(1):H61-H69

PubMed: 30359076 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Am J Transl Res, 2019, 11(10):6534-6543

PubMed: 31737204 ( click the link to review the publication )
Am J Transl Res, 2019, 11(12):7255-7271

PubMed: 31934276 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7265

PubMed: 31524277 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

PLoS One, 2019, 14(5):e0216603

PubMed: 31100067 ( click the link to review the publication )

Reprod Sci, 2019, 1933719119828067

PubMed: 30791863 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Exp Ther Med, 2019, 18(3):2278-2284

PubMed: 31410178 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

ACS Pharmacol Transl Sci, 2019,

PubMed: 32259061 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2018,

PubMed: 30224486 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )
Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Virulence, 2018, 9(1):83-98

PubMed: 28475412 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )
Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )
Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Sci Signal, 2017, 10(507)eaam7550

PubMed: 29184034 ( click the link to review the publication )

J Med Chem, 2017,

PubMed: 28471660 ( click the link to review the publication )

Cancers (Basel), 2017, 9(9)E125

PubMed: 28926938 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):102-115

PubMed: 27980105 ( click the link to review the publication )

Mol Oncol, 2017, 11(9):1130-1142

PubMed: 28544747 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10612

PubMed: 28878291 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12406

PubMed: 28963527 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )
World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Cell Cycle, 2017, 16(21):2146-2155

PubMed: 28910567 ( click the link to review the publication )

Oncotarget, 2017, 8(50):88043-88058

PubMed: 29152140 ( click the link to review the publication )

Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7265-7275

PubMed: 27980219 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

Cancer Lett, 2016, 374(2):250-60

PubMed: 26921131 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Biol Chem, 2016, 397(7):671-8

PubMed: 26910743 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65627-65642

PubMed: 27582537 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )
Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(34):54883-54896

PubMed: 27448972 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19214-27

PubMed: 27036037 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1593

PubMed: 25590803 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )
Cancer Sci, 2015,

PubMed: 25483727 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

BMC Cancer, 2015,

PubMed: 26205886 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26270481 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )
EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Sci Signal, 2014, 7(349):ra102

PubMed: 25351247 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )
Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12862-76

PubMed: 25404640 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )
Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

J Biol Chem, 2013, 288(41):29821-35

PubMed: 23963458 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012,

PubMed: 22989520 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

靶点

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	点击更多
4 nM	5 nM	6 nM	7 nM	21 nM	点击更多

体外研究

BEZ235显著降低mTOR活化的激酶p70S6K的磷酸化水平。BEZ235导致S235/S236P-RPS6水平减少，IC50为6.5 nM。BEZ235抗mTOR的活性使用生化mTOR K-LISA试验测定，IC50为20.7 nM。BEZ235对其β旁系同源物的活性稍弱，IC50为75 nM。在人肿瘤细胞中，PI3K/Akt/mTOR通路经常被组成性活化。BEZ235阻断PI3K和mTOR激酶活性，通过结合于这些酶的ATP结合槽发挥作用。用逐渐增加浓度BEZ235处理PTEN-null细胞系PC3M和U87MG时，导致细胞增殖剂量依赖性减少，平均GI50为10-12 nM。^[1] BEZ235是一种mTORC1/2催化抑制剂。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	NEHENVRCdnSrbXnjdo9jcWGuIFHzd4F6		MWKxPEBp	MoLiSG1UVw>?	M3X1OGFvfGm2conwZY5we2:vYXygZYN1cX[rdImge4l1cCCHQ{WwJI9nKDBwMECyOUDPxE1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUm0Okc,OjR6MEW5OFY9N2F-
MCF7	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknONE4xOS1zMECg{txO	MYS0PEBp	MXHEUXNQ	Mn\5TWM2OD1yLkezJO69VQ>?	M1;ZUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEexPVA1Lz5{M{i3NVkxPDxxYU6=
HCT116	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fvdlAvODFvMUCwJO69VQ>?	NGi5OVg1QCCq	NUPXRZoyTE2VTx?=	NX\VVpdIUUN3ME2xMlE3KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5MUmwOEc,OjN6N{G5NFQ9N2F-
U87MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkm0NE4xOS1zMECg{txO	NGG5ZnI1QCCq	MV;EUXNQ	NF:y[I9KSzVyPUGuN\|Ih\|ryP	NFrtWnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3NVkxPCd-MkO4O\|E6ODR:L3G+
HBC4	NUCwb49YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIqxZVQxNjBzLUGwNEDPxE1?	NHnNPYw1QCCq		NXvkcXR2VG:pIFfJOVA:NThwNkGgUS=>	MnnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
BSY1	MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DxWlAvODFvMUCwJO69VQ>?	MU[0PEBp		NFH0bolNd2diR1m1NF0uQC52ODDN	NHG0TmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HBC5	NIrMXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\Pfo8xNjBzLUGwNEDPxE1?	NGrrXYw1QCCq		M1LoTmxw\yCJSUWwQU04Njh5IF2=	NWDteVFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MCF7	NVPXUpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmwMlAyNTFyMDFOwG0>	MW[0PEBp		NV3aepR{VG:pIFfJOVA:NThwMU[gUS=>	M2e4SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MDA-MB-231	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInBN\|cxNjBzLUGwNEDPxE1?	NX\LUJdXPDhiaB?=		MoTqUI9oKEeLNUC9MVgvODliTR?=	MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
U251	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjhSnExOC5yMT2xNFAh\|ryP	NVq3clEyPDhiaB?=		MlmzUI9oKEeLNUC9MVcvPjZiTR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF268	NUXaPYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\ubHV6OC5yMT2xNFAh\|ryP	MlnzOFghcA>?		MXTMc4chT0l3ME2tO{46OiCP	Ml;TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF295	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4e3T\|AvODFvMUCwJO69VQ>?	NFvKWpc1QCCq		Mmr6UI9oKEeLNUC9MVgvOzFiTR?=	NEjDc2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SF539	M4rUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\sNE4xOS1zMECg{txO	MUm0PEBp		MYnMc4chT0l3ME2tPE42QSCP	MoLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SNB75	M4ricGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[1NE4xOS1zMECg{txO	MUe0PEBp		M1PCSWxw\yCJSUWwQU05NjV6IF2=	NUi5WWNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
SNB78	NEDVbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\VeVAvODFvMUCwJO69VQ>?	MWO0PEBp		NXf4fm45VG:pIFfJOVA:NThwNkWgUS=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
HCC2998	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHoe4liOC5yMT2xNFAh\|ryP	NE\nWok1QCCq		MVvMc4chT0l3ME2tPE4xPSCP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
KM12	MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n2[VAvODFvMUCwJO69VQ>?	NX;C[Y5MPDhiaB?=		M{j0XWxw\yCJSUWwQU04NjV2IF2=	NVTO[mM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HT-29	M2m1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWSwMlAyNTFyMDFOwG0>	NHTndoc1QCCq		NHe2SVZNd2diR1m1NF0uPy55NTDN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
HCT15	M2G5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfTNWpbOC5yMT2xNFAh\|ryP	MUW0PEBp		NXLMdnVJVG:pIFfJOVA:NThwMEOgUS=>	NYrqT5pTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HCT116	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnGyNE4xOS1zMECg{txO	NUDQXYVmPDhiaB?=		NVHTVXZFVG:pIFfJOVA:NTdwNkGgUS=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
NCI-H23	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XpblAvODFvMUCwJO69VQ>?	NIjkUlk1QCCq		M2n5Omxw\yCJSUWwQU04NjZ2IF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
NCI-H226	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HLSVAvODFvMUCwJO69VQ>?	NHy0VmM1QCCq		NH\xUIJNd2diR1m1NF0uQC52NDDN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
NCI-H522	NXfGSWJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYKwMlAyNTFyMDFOwG0>	MlO5OFghcA>?		M33mR2xw\yCJSUWwQU05NjR3IF2=	NHPmVZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H438	NWDCPXNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDNXHIxNjBzLUGwNEDPxE1?	MUG0PEBp		MWLMc4chT0l3ME2tPE4yOSCP	NGPrVlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
A549	M4\lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPsNE4xOS1zMECg{txO	NEH6SnE1QCCq		MYLMc4chT0l3ME2tPE4xPyCP	Ml[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS273	NITIUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUj2RlhIOC5yMT2xNFAh\|ryP	MXO0PEBp		MYPMc4chT0l3ME2tO{45OCCP	MmfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS114	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7XcIhzOC5yMT2xNFAh\|ryP	MYi0PEBp		NY\KdlM5VG:pIFfJOVA:NThwM{mgUS=>	MnnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
LOXIMVI	NUXoSWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHEWmkxNjBzLUGwNEDPxE1?	NVW1R2dIPDhiaB?=		M2\ybWxw\yCJSUWwQU05NjZ4IF2=	MmX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvFSJkxNjBzLUGwNEDPxE1?	NH\2bXM1QCCq		MmrGUI9oKEeLNUC9MVgvOTdiTR?=	NXjJTWU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR4	NFTzU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TEcFAvODFvMUCwJO69VQ>?	M2T2bVQ5KGh?		Mn75UI9oKEeLNUC9MVgvPThiTR?=	NGfvNmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
OVCAR5	NXrkWXBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXFRpUxNjBzLUGwNEDPxE1?	Mle5OFghcA>?		NInWUGFNd2diR1m1NF0uPy53NzDN	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR8	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUWwMlAyNTFyMDFOwG0>	M3PJNFQ5KGh?		M2TRbWxw\yCJSUWwQU04Njh2IF2=	NEn3c2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SKOV3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2wMlAyNTFyMDFOwG0>	NEDNVoQ1QCCq		MnHVUI9oKEeLNUC9MVgvPDFiTR?=	NITPbok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
RXF631L	Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXIcYMxNjBzLUGwNEDPxE1?	NF3EPIc1QCCq		NUDqUnoyVG:pIFfJOVA:NThwMkGgUS=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
ACHN	NHrOcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPmVW8xNjBzLUGwNEDPxE1?	M2PD[VQ5KGh?		NFHIfWFNd2diR1m1NF0uPy57NTDN	NHS0doI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
St-4	MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjIc4gxNjBzLUGwNEDPxE1?	NXruSGNMPDhiaB?=		MkGyUI9oKEeLNUC9MVcvPDdiTR?=	NEjIdpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN1	M{W2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUmwMlAyNTFyMDFOwG0>	MlSyOFghcA>?		M2TBdGxw\yCJSUWwQU05NjRzIF2=	NV2ydYN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN7	M{iwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKwMlAyNTFyMDFOwG0>	M{W1O\|Q5KGh?		M1v4VWxw\yCJSUWwQU04NjZ6IF2=	M1TRdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN28	NUTLW5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfRWotVOC5yMT2xNFAh\|ryP	M3fzZlQ5KGh?		MWjMc4chT0l3ME2tO{4xPyCP	M4HCRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN45	NFP2RmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:wMlAyNTFyMDFOwG0>	MUW0PEBp		NV7weVY5VG:pIFfJOVA:NThwM{SgUS=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MKN74	NYTm[YduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXKwMlAyNTFyMDFOwG0>	MXO0PEBp		M4nkNmxw\yCJSUWwQU04NjR{IF2=	NXXZZYl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
DU145	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmwMlAyNTFyMDFOwG0>	MofUOFghcA>?		NITRNINNd2diR1m1NF0uQC5zNjDN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
PC3	M1raSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfudG0xNjBzLUGwNEDPxE1?	NI\WR\|Q1QCCq		MWLMc4chT0l3ME2tPE43PiCP	M37oNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
Trypanosoma brucei brucei	NWfkOIJ1TnWwY4Tpc44hSXO\|YYm=	MknXNlAxKG6P	MVexNkBp	NYTEbZVjTE2VTx?=	M2nkPGRm[3KnYYPlJIlvKHCqb4PwbI91cWS7bDDpco9{cXSxbDDwbI9{eGijdHWgcIV3\Wx?	NEjoT5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVk1Pid-MkS4NFU6PDZ:L3G+
Trypanosoma brucei brucei	NUD2WolXTnWwY4Tpc44hSXO\|YYm=		NGrZVXcyQCCq	M{jBVmROW09?	MmT0TY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	M3rsS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1PVQ3Lz5{NEiwOVk1PjxxYU6=
Trypanosoma brucei brucei	NGrNO2lHfW6ldHnvckBCe3OjeR?=	Mn\zNlAxKG6P	MWSxNkBp	M13NcmROW09?	Ml3DSYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw>	MlfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEW5OFYoRjJ2OEC1PVQ3RC:jPh?=
Trypanosoma brucei brucei	NFXPbHFHfW6ldHnvckBCe3OjeR?=	Ml30NlAxKG6P	MVexNkBp	NXL4SFhVTE2VTx?=	MnPFSYZn\WO2IH;uJJBpd3OyaHH0bYR6dGOqb3zpcoUhdGW4ZXy=	M3\3SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1PVQ3Lz5{NEiwOVk1PjxxYU6=
UM-UC-3	NVPYS5JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnq0TWM2OD1\|MUWgdG0>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SBC-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHlWJJXUUN3ME23OFIheE1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MKN1	NGTIWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk[2TWM2OD1{Lkigcm0>	NH\PSlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H720	NVrQd\|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrnTWM2OD1\|LkW3JI5O	M1rwd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BFTC-909	NX30dIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDDTWM2OD1\|LkexJI5O	NWOydHR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BPH-1	M2L5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHjWVlqUUN3ME20Mlc3KG6P	NX\WfXZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
PC-3	M1vl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTVwMEmgcm0>	NHzYcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
AN3-CA	NHXZXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2L0TmlEPTB;NT61OkBvVQ>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HN	NEXVTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLmTWM2OD13Lkm2JI5O	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HCC2218	M3HSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTZwNkGgcm0>	NUf1bZdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KP-4	NHTW[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLHdpZKSzVyPUegcm0>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LU-139	M1jXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWG0TXF[UUN3ME23Mlc4KG6P	M4PHPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ETK-1	M2jkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjwdolwUUN3ME23Mlg5KG6P	Ml64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	M2XKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXrTWM2OD16LkS5JI5O	M3X5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MHH-PREB-1	M3nXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2T2NGlEPTB;OT6xNkBvVQ>?	NGPuOZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DU-4475	MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnu4TWM2OD17LkS0JI5O	MkLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1666	NV;OZmRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDLTVRKSzVyPUmuO\|Ehdk1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAMA-1	Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPPZZo{UUN3ME25Mlghdk1?	NFnvdmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TYK-nu	M4XhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTlwOUSgcm0>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MFE-280	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fNNWlEPTB;OT65PUBvVQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A549	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTFyLkG0JI5O	M{i0NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
769-P	M1e3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULJN5dEUUN3ME2xNE41PCCwTR?=	NGPXXYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
L-363	M1;0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\ITWM2OD1zMD62PUBvVQ>?	M4LFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ES8	MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fXW2lEPTB;MUCuPUBvVQ>?	NVfsTJhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
PA-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPFTWM2OD1zMT64NkBvVQ>?	NHS2e4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Mewo	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGG0VGNKSzVyPUGxMlk6KG6P	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HSC-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1r1UWlEPTB;MUKuNlEhdk1?	NF;DO5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
H4	NUDTWIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3njR2lEPTB;MUKuOlchdk1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BB65-RCC	M1Lae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXmTWM2OD1zMj63NkBvVQ>?	M2XhUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1793	NVTTUZltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFWx[\|JKSzVyPUGyMlgzKG6P	MmfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KARPAS-45	NGfvS\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r1fmlEPTB;MUOuOVEhdk1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GCT	M37NT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7pTWM2OD1zMz62PEBvVQ>?	NU\G[2ZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EoL-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF\|LkmzJI5O	M4TVNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LB2241-RCC	NHr2OWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LERWlEPTB;MUSuNFEhdk1?	M1\zUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ES5	NIDHeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\KOmlEPTB;MUSuO\|Qhdk1?	M33ZXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LOXIMVI	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnGfnVKSzVyPUG0Mlk6KG6P	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COR-L105	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF3LkC0JI5O	MkTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
P12-ICHIKAWA	NIDaSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zTUWlEPTB;MUWuNUBvVQ>?	Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CHL-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HFdmlEPTB;MUWuOFUhdk1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfGRVRKSzVyPUG1MlY{KG6P	M2S3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HH	NHLqWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTCdGt7UUN3ME2xOU44KG6P	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NUGC-3	NGDQeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\4dVFKSzVyPUG2MlM1KG6P	M2L4dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EGI-1	NFjKV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{foeWlEPTB;MU[uOFMhdk1?	M2fUdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OS-RC-2	NXTkepliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn5N5hKSzVyPUG2MlQ4KG6P	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MOLT-16	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrmbmFKSzVyPUG3MlE2KG6P	NUH4OplXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H209	NHe3TXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzOfY5rUUN3ME2xO{4zQSCwTR?=	NF7D[oQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
697	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrDTWM2OD1zNz60N{BvVQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
D-56MG	NVHZW2JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH2xUGJKSzVyPUG3MlY6KG6P	M1;RblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
VA-ES-BJ	M2PTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTF5LkizJI5O	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EW-16	NIKxO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF6LkC0JI5O	MlzyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HGC-27	MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LhPGlEPTB;MUiuNFYhdk1?	NFvjUVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES7	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLMTWM2OD1zOD6wPUBvVQ>?	M1LkblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HuH-7	M2PHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPCTWM2OD1zOD60JI5O	NFvQPWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BCPAP	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTF6Lk[1JI5O	NVnsZlZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1710	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTF6LkeyJI5O	MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
IST-MEL1	M4[0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTF6Lke3JI5O	Moq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SF295	NYTUdZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4r5ZWlEPTB;MUiuPVMhdk1?	MkGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RPMI-7951	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnG3TWM2OD1zOT6yPEBvVQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SF126	M1fYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFX0cnVKSzVyPUG5MlQyKG6P	NILjdJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GAMG	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX:xR4sxUUN3ME2xPU41QCCwTR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KNS-81-FD	NXPFOo5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfYTWM2OD1zOT61OEBvVQ>?	M4fTNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RT-112	NX\jPFNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDS[Y1XUUN3ME2xPU43PiCwTR?=	MlTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DEL	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zIPGlEPTB;MkCuOFkhdk1?	NETjc5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CGTH-W-1	NH65[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\iZopKSzVyPUKwMlY{KG6P	M3vGR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HOS	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojsTWM2OD1{MT6wOkBvVQ>?	NYfMZpczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ES4	NIjLbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4m3dGlEPTB;MkGuNFghdk1?	NUDwVZZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RXF393	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJzLkS1JI5O	Ml;XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2030	NXfZTnVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJzLkWyJI5O	MmfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
YH-13	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHT2SJZKSzVyPUKxMlg5KG6P	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HT-1080	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfRVHpKSzVyPUKxMlk{KG6P	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vnNGlEPTB;MkGuPVUhdk1?	NUHk[ZhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
G-402	M{T5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mne0TWM2OD1{Mj6xOkBvVQ>?	M2flcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
786-0	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHHVYpKSzVyPUKyMlI6KG6P	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ME-180	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPIVWJNUUN3ME2yNk41OyCwTR?=	M2\Hc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NB69	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\rOYhKSzVyPUKyMlU{KG6P	M4PDc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
J-RT3-T3-5	NIrxVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\3[IZKSzVyPUKyMlk3KG6P	NESxfYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TGBC1TKB	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2D1Z2lEPTB;MkOuNFUhdk1?	M13CflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW780	M4fkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXCXoNKSzVyPUKzMlE{KG6P	MkHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MG-63	NHP6SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rpW2lEPTB;MkOuOFUhdk1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BV-173	MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTJ\|Lki3JI5O	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-51	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3hWnZKSzVyPUKzMlg6KG6P	NFLGRmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A375	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrFUYZxUUN3ME2yN{46OyCwTR?=	M2jUVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MEL-HO	NHmyPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjMfZJnUUN3ME2yOE4xPCCwTR?=	NHLLVVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EFO-27	NF7aVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\iNmJJUUN3ME2yOE4{OyCwTR?=	NHL6dYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Hs-578-T	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fDZmlEPTB;MkSuOVghdk1?	NFnreGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NBsusSR	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHEbnlKSzVyPUK0MlYhdk1?	Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CTB-1	NH;yN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[1TWM2OD1{ND62O{BvVQ>?	MlHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
FTC-133	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjKWnNKSzVyPUK1MlEhdk1?	NFvsbJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MOLT-4	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrFb3dKUUN3ME2yOU4yOiCwTR?=	NWjvUIhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HO-1-N-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfu[W1KSzVyPUK1MlE2KG6P	NIT4d4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES3	NYjvZWp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TSe2lEPTB;MkWuNlIhdk1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TI-73	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PhOGlEPTB;MkWuNlghdk1?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MPP-89	NIG4PYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknpTWM2OD1{NT6zNkBvVQ>?	M3j6[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-150	NVG1Z2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX72cpFrUUN3ME2yOU45QSCwTR?=	NVLRRmJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LXF-289	NXTXNYk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnH5TWM2OD1{Nj6wOEBvVQ>?	M2HweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-LU-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXEVVVKSzVyPUK2MlE4KG6P	NFHZbZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HOP-92	NEXZXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu1TWM2OD1{Nj60PEBvVQ>?	NGHCWoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HuO9	NHTWVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJ4Lke2JI5O	Ml;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW962	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HQbWlEPTB;Mk[uO\|Yhdk1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RS4-11	NXXrPYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHW[VdKSzVyPUK2MlkyKG6P	NEn3bWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H292	Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIm4WIhKSzVyPUK3JI5O	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
DB	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j5NWlEPTB;MkeuN\|Yhdk1?	MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1088	NYHqSZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn20TWM2OD1{OD6yPUBvVQ>?	M17OdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A204	NX:0O5lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfYZm1FUUN3ME2yPE41PyCwTR?=	NVTmd2k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A3-KAW	MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nwZmlEPTB;MkiuOlQhdk1?	NFLBVZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MV-4-11	NUS3SXliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzFTWM2OD1{OD63JI5O	M{jWTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ES1	NHXDe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXCXodKSzVyPUK4Mlg1KG6P	M{foTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ONS-76	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rO[2lEPTB;MkmuNFUhdk1?	M2P3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
D-263MG	NYjVTFNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVP5fYpyUUN3ME2yPU4{PSCwTR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
U-2-OS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTJ7LkWgcm0>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
T98G	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHTc\|JGUUN3ME2yPU45QCCwTR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GI-ME-N	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\UbmlEPTB;MkmuPVEhdk1?	NEDme3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BHT-101	M{j3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHhWXhKSzVyPUOwMlA2KG6P	MkjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NOS-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoK5TWM2OD1\|MD6xNkBvVQ>?	NH\xVlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
AsPC-1	NG\nW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPuTWM2OD1\|MD6yJI5O	M{HM[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
QIMR-WIL	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{K5ZmlEPTB;M{CuOkBvVQ>?	NX;QPZRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
JVM-3	M3\UWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;CTWM2OD1\|MD64N{BvVQ>?	NGXkd2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KU-19-19	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnac4dKSzVyPUOxMlE{KG6P	M4\idlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OVCAR-8	NGLZS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLnNnU1UUN3ME2zNU4zPiCwTR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BEN	NGjsfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkn5TWM2OD1\|MT62N{BvVQ>?	M1vOeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BE-13	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTNzLkiyJI5O	M3LGUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EW-18	NFvtU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\j[WlEPTB;M{GuPFYhdk1?	NF7VV4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ECC10	M13RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPRWY5GUUN3ME2zNU46PSCwTR?=	NE[yfFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CTV-1	NHzkfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\ETWM2OD1\|Mj64NkBvVQ>?	NUHKPHh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-800	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:2OWVKSzVyPUOyMlkzKG6P	M2nWXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A2058	NVXabVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X6NGlEPTB;M{OuNlUhdk1?	NWPuZWN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
VM-CUB-1	NVvDSYdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Oyb2lEPTB;M{OuOFMhdk1?	NI\neY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Ca9-22	NVGzU\|dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFy1XppKSzVyPUOzMlU2KG6P	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COLO-684	M1vKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnm4TWM2OD1\|Mz61PEBvVQ>?	NULlSlBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RPMI-8226	NW\ESGRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTN\|LkiyJI5O	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUezNIo5UUN3ME2zOE4yPSCwTR?=	MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Becker	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYCzOm9SUUN3ME2zOE4zOSCwTR?=	NYL1bWJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H28	NXTJR5hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfyToFpUUN3ME2zOE41PCCwTR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAL-120	NUPCPI9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTN2LkeyJI5O	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MDA-MB-157	NYjiSHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrXfHI{UUN3ME2zOU41OSCwTR?=	NYD1[GdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OVCAR-5	NFXBc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTN3LkS3JI5O	NGTUUWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LAMA-84	NWnzTIZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjmZY01UUN3ME2zOU45PyCwTR?=	MnzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAKI-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnVeHNuUUN3ME2zOk41OyCwTR?=	MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Daoy	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTN4Lkegcm0>	NFvIWFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-62	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDoTWM2OD1\|Nj64OkBvVQ>?	Mo\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
8-MG-BA	NGXiT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rJOmlEPTB;M{euNlUhdk1?	NEPBNJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
8505C	M4\TWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\PdGlEPTB;M{euOVEhdk1?	M37HUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LNCaP-Clone-FGC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7mOlBKSzVyPUO3MlU6KG6P	NX\oPGUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-39	M2rEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGm4RY1KSzVyPUO3Mlkhdk1?	M3S5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MN-60	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHLVolWUUN3ME2zO{46PiCwTR?=	M{jFSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RKO	NELU[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTN6LkOzJI5O	MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
U251	NELhUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTN6LkSzJI5O	M2e2RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SJSA-1	NWD1R4lKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPPZYdKSzVyPUO4MlU1KG6P	NImzepE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-12T	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnn1TWM2OD1\|OD62JI5O	M{jPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HCC1419	M1;QXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTN6LkexJI5O	NXHYclN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CO-314	NU\1fmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zNcmlEPTB;M{iuO\|Qhdk1?	NE\5Tno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LB1047-RCC	M4XrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:1TINyUUN3ME2zPE45OSCwTR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A101D	M3HQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTN6Lkm3JI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MDA-MB-175-VII	M2fpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXsdoJKSzVyPUO5MlUyKG6P	M3S4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MZ2-MEL	NW\ORYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrpcWRKSzVyPUO5MlY3KG6P	MnjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NB5	MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEWyTlhKSzVyPUSwMlY1KG6P	M{X1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
G-401	NWLGflVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTRyLkiyJI5O	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HT	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVmwTXFQUUN3ME20NU4xOiCwTR?=	MoLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
8305C	NVrRdFFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDxR\|R{UUN3ME20NU45PyCwTR?=	MnHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BHY	NYqySJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTR{LkeyJI5O	M2ftXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTR\|IH7N	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
T-24	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\wS41KSzVyPUSzMlg{KG6P	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EPLC-272H	NUTCVWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGW1TGlKSzVyPUS0MlM6KG6P	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PSN1	NXTHVmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXhSnpWUUN3ME20OE41KG6P	M2TzSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H2452	NIXacohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MniwTWM2OD12ND61PEBvVQ>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KS-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\mTWM2OD12ND62OkBvVQ>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	M{LrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHQfnF2UUN3ME20OE46OiCwTR?=	Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KNS-62	NVL6NotiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3f4cWlEPTB;NEWuN\|ghdk1?	M{\OVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NOMO-1	MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TZUmlEPTB;NEWuPFchdk1?	M1G3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-HEP-1	NF2w[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4npNmlEPTB;NE[uNFQhdk1?	M1u3V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGR-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTR4LkGzJI5O	M4XpcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-180	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPaTWM2OD12Nj6xO{BvVQ>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EW-22	M4Pwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mme1TWM2OD12Nj6yJI5O	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1355	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPFOJRKSzVyPUS2MlM1KG6P	M1fyTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
DOHH-2	M3v6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoiyTWM2OD12Nj6zO{BvVQ>?	M4LBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A4-Fuk	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzPO3lHUUN3ME20Ok42OiCwTR?=	Mlm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
PC-14	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVO5eJRVUUN3ME20Ok42PyCwTR?=	NFHsSFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TE-5	NETUXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTR4Lki0JI5O	M2jiRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LB996-RCC	M4e5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTR5LkG5JI5O	NH\HZXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1623	NIPhOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEThPJlKSzVyPUS3Mlc3KG6P	Mn3EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1155	NHHQNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTR6LkOyJI5O	MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LoVo	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHGzdHFKSzVyPUS4MlQhdk1?	NUHsXXdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MCF7	MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYiy[ZROUUN3ME20PE42QCCwTR?=	M4PJ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
AGS	NGLpSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPrVYpyUUN3ME20PE44PyCwTR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PFSK-1	NGXaTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVP1UnZyUUN3ME20PU4xPiCwTR?=	NELsTm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
22RV1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LySmlEPTB;NEmuNFkhdk1?	MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
COR-L23	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTR7LkG2JI5O	NYPyTmpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
D-283MED	M{\ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fXb2lEPTB;NEmuOlEhdk1?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW982	M3vWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTR7LkmxJI5O	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW620	NG\GcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfHcmROUUN3ME21NE4{PiCwTR?=	M2DDXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-140	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHHTWM2OD13MD61OUBvVQ>?	NFrHSZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GCIY	NIG3[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTVyLk[3JI5O	MljzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MHH-ESS-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLibZhGUUN3ME21NU46PSCwTR?=	NHzFWZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-423MG	NUj5UIVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\RTWM2OD13Mj6wPEBvVQ>?	NVPmW5JnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SF539	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPXTWM2OD13Mj6zOUBvVQ>?	MofTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RPMI-2650	NWj1[5QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTV{Lk[5JI5O	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GR-ST	NWP3OZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkS3TWM2OD13Mj64O{BvVQ>?	NIfGSow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
YKG-1	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTV\|IH7N	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SK-MES-1	M1S5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEniWIRKSzVyPUWzMlI3KG6P	NIGxdGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HLE	NYDodm0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTV\|LkS3JI5O	MmfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RVH-421	M{L5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTV\|Lk[3JI5O	NHi2RZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
C32	NVzPWYpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXn1TYdsUUN3ME21N{45OyCwTR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GB-1	NVfMeGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX2yNWc1UUN3ME21OE4zKG6P	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SNB75	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\GU4REUUN3ME21OE4zPiCwTR?=	NGX1UVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EM-2	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWraTYxGUUN3ME21OE41KG6P	NYn1N5JoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RH-1	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTFZ49KSzVyPUW0Mlchdk1?	NHezblg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NKM-1	NV\SSYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHi5RopKSzVyPUW0MlgyKG6P	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2405	Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVOxbYt7UUN3ME21OE45QCCwTR?=	Mo\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-450	NVX4NWNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjNU3pKSzVyPUW1MlE3KG6P	M4jYNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A704	M1PoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTFSnVjUUN3ME21OU42QSCwTR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HAL-01	NInMWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnP1TWM2OD13NT64N{BvVQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-11	MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHmT2NrUUN3ME21OU46QSCwTR?=	NXzWdVF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DOK	NFXGRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{D1WGlEPTB;NU[uNFIhdk1?	M2\sUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KY821	NGSxZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3OzeGlEPTB;NU[uNkBvVQ>?	NWrTNXZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KGN	NGDOd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:5NmV5UUN3ME21Ok4{OiCwTR?=	MmHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MC116	MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XmSGlEPTB;NUeuPEBvVQ>?	NUP5R\|dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
PANC-08-13	NIK2U4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2qx[2lEPTB;NUiuNFEhdk1?	M4HoVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KE-37	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHz5PGRKSzVyPUW4Mlc4KG6P	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-410	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTV7LkS3JI5O	NIT3bpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RO82-W-1	M1v0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTV7Lkmgcm0>	NIS0dnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
M14	NGPKV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjxeJBKSzVyPU[wMlA1KG6P	Mm\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GI-1	NH7nc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPrO41pUUN3ME22NE4{KG6P	MontQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ML-2	M{C1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TMfWlEPTB;NkCuOlIhdk1?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BFTC-905	M1jzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2P1fGlEPTB;NkCuOlUhdk1?	NXmzVVFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DMS-273	NYn2doxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTZyLki3JI5O	NEG3S2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MDA-MB-361	M4XKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13HdGlEPTB;NkGgcm0>	NWOwTWh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MSTO-211H	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmOxTWM2OD14Mz61NUBvVQ>?	NV\5b2FnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MEG-01	NIrHTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfOTWM2OD14Mz61NkBvVQ>?	M2LRV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
M059J	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LZWGlEPTB;NkOuOVghdk1?	NXn4O5BoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LN-405	NFzX[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnKbFBKSzVyPU[zMlg2KG6P	NVXkZpVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1581	M{LhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[3[FNnUUN3ME22OE4xOyCwTR?=	Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TCCSUP	NF3zdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTZ2LkWzJI5O	MnPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW872	NWj5fnBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjod5hKSzVyPU[0MlU4KG6P	NV7UfIM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-510	M3LCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPaTWM2OD14NT63OUBvVQ>?	MlXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1792	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\5[\|A{UUN3ME22Ok4yPSCwTR?=	Ml3FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW13	NWfUUpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTZ4LkWgcm0>	NHfLbIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TE-8	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPlUXQ4UUN3ME22Ok42OiCwTR?=	MlzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SCH	NY\ufm0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTZ5LkGgcm0>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NEC8	NH\iN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\CTWM2OD14Nz6yOEBvVQ>?	M13ONlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HuO-3N1	M2P1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkH1TWM2OD14Nz6zNUBvVQ>?	Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EFM-19	MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnMOG8zUUN3ME22O{42KG6P	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HEC-1	M1r1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTnTWM2OD14Nz61NkBvVQ>?	NYrEe\|VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
T47D	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfQTWM2OD14Nz64O{BvVQ>?	NWjCb3p[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SNU-423	NH76TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTZ5Lkm4JI5O	M1GwS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
WM-115	M1fXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\qdpFkUUN3ME22PE4yPCCwTR?=	M2XvXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CaR-1	MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13JTWlEPTB;NkiuNlUhdk1?	M2DsO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KU812	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;kTGZ6UUN3ME22PE43QSCwTR?=	NYrCTmhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
AM-38	NIrlNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTZ7LkOxJI5O	NVXwdnlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KOSC-2	M1vMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfYO\|Y1UUN3ME22PU46PyCwTR?=	MkexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MC-IXC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW1TWM2OD15MD6wPEBvVQ>?	MoTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SCC-4	NFjucFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTdzLkO4JI5O	MlfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Calu-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7VTWM2OD15MT65PEBvVQ>?	NGfXUGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RPMI-8866	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjpbIpVUUN3ME23Nk45OiCwTR?=	M1;kRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OVCAR-4	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPFUnZwUUN3ME23N{4{PiCwTR?=	Mk\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OAW-42	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzxV2dKSzVyPUezMlM6KG6P	M1m0OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ATN-1	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXaTWM2OD15Mz64O{BvVQ>?	MnXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CHP-212	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTd2Lkm1JI5O	M3vRRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
C2BBe1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXZUm1KSzVyPUe1MlA{KG6P	NVv4eXVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
A498	NE\vRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIf2c3dKSzVyPUe1MlE2KG6P	M1HjSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SH-4	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFmwN2lKSzVyPUe1MlIyKG6P	M3vtOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SNU-449	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTd3Lke5JI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RD	NGHTVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTd3Lki2JI5O	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
PANC-03-27	M1uwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz6TWM2OD15Nj6yOUBvVQ>?	NX:zN\|Q2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
S-117	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7FeIRDUUN3ME23Ok4zPyCwTR?=	NH30V4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-MEL-2	M2fZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3faeGlEPTB;N{[uO\|Uhdk1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LK-2	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTJdHVTUUN3ME23O{4xPSCwTR?=	MmXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CP50-MEL-B	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3X0OGlEPTB;N{euOEBvVQ>?	NYTYblN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
647-V	NVzTXoNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33NbGlEPTB;N{iuNFchdk1?	NGLlWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LU-134-A	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTd7LkCzJI5O	NHTwe3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
5637	NGSzSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPWTWM2OD15OT6yN{BvVQ>?	NWXNdo16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1437	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7FTYxKSzVyPUiwMlUhdk1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H460	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\aTWM2OD16MT6yN{BvVQ>?	M1HUeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BxPC-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPRXGRKSzVyPUixMlQ3KG6P	M4rGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAN	M2jvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33PSWlEPTB;OEGuPFQhdk1?	M{TYfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KINGS-1	MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXETWM2OD16Mj6zNkBvVQ>?	M1;JTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OCUB-M	M132PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\OOmlEPTB;OEKuOFEhdk1?	M{XuUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KALS-1	NIruSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7kTWM2OD16Mj61OEBvVQ>?	NVjrZmx{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OCI-AML2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTh{Lk[xJI5O	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A253	NYDvb49DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHj1c4hKSzVyPUiyMlY2KG6P	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LCLC-97TM1	M1HS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTh{Lki2JI5O	NGDrR4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H520	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7XWnUxUUN3ME24N{4xPiCwTR?=	NWX2[XZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
P30-OHK	NFjyfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XDVmlEPTB;OEOuOUBvVQ>?	MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SBC-5	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPCTWM2OD16Mz61NkBvVQ>?	NIDxbYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCE-T	M2W0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fVWGlEPTB;OEOuO\|Qhdk1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
JEG-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jQdGlEPTB;OESuNUBvVQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KG-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDCPWRKSzVyPUi0MlI1KG6P	M3OyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MIA-PaCa-2	M{CzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rHTmlEPTB;OESuOVQhdk1?	Mln6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-33	NHz2OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTh3LkC4JI5O	MkX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
639-V	NVPSRlc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXTTWM2OD16NT60NkBvVQ>?	NELjSI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1048	NYjPNI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLoTWM2OD16Nj6zNUBvVQ>?	M2TocVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1573	NHnHZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTh5LkS4JI5O	NE\KWpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H2228	M1PUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTh6LkK2JI5O	NU[1bJg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NB14	NX36bIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHKSnNKSzVyPUi4MlMhdk1?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SCC-25	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTh7LkiyJI5O	NF;DZYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A431	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfOTWM2OD16OT65O{BvVQ>?	NXXxN5h4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SN12C	MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3W2SmlEPTB;OUCuOlIhdk1?	Mle3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HuCCT1	M2X3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XFd2lEPTB;OUCuO\|Yhdk1?	NVjrO\|BJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LS-123	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVq5Z\|VpUUN3ME25Nk4yQCCwTR?=	M3TP[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAL-85-1	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1i0XmlEPTB;OUKuOFghdk1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ES6	M3\KTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\GUZJvUUN3ME25Nk45OyCwTR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H650	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX6wSpE6UUN3ME25OE4xQSCwTR?=	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H446	M4\hXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jMe2lEPTB;OUWuNVIhdk1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EW-13	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;1e3ZnUUN3ME25OU44PSCwTR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HSC-2	Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnkT\|J7UUN3ME25OU45QSCwTR?=	NIrObYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
U031	NHn3OIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTl4LkezJI5O	M{XYblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EW-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrSVnk2UUN3ME25Ok45QCCwTR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
GAK	M3rlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTl6LkmzJI5O	NWTqVY9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-OV-3	M4PncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTWTWM2OD1zMECuNFchdk1?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
OMC-1	M2\IR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13WeGlEPTB;MUCwMlE5KG6P	M1LaUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TK10	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEG0[\|JKSzVyPUGwNE4zOSCwTR?=	NEnoOnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
EKVX	M2nGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHmTWM2OD1zMECuOkBvVQ>?	NGTmU2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Detroit562	NI[3OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrMTWM2OD1zMEKuNVchdk1?	MmPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SF268	MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTFyMj6zOEBvVQ>?	M{jMZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SNU-387	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPuTWM2OD1zMESuNVchdk1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MDA-MB-231	NEe4cW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfTN49YUUN3ME2xNFUvODZibl2=	M4fIWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1563	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYL3[4NRUUN3ME2xNFUvOThibl2=	MnPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-502MG	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\RVWlEPTB;MUC1Mlchdk1?	M3rPZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A2780	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkX0TWM2OD1zME[uOFchdk1?	M1zUTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IA-LM	M2PqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nOOmlEPTB;MUC3MlUyKG6P	NEnjTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-392MG	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fubmlEPTB;MUC3MlU1KG6P	NInWNHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MS-1	NV:5N2t5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTnTWM2OD1zMEeuO\|Ehdk1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW1990	M4i4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVj6dZFRUUN3ME2xNFgvPTRibl2=	NVzZNHQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HEL	NYjVdWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnEbpdvUUN3ME2xNFkvOjlibl2=	M4fDe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1573	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVracFZmUUN3ME2xNFkvOzFibl2=	NIrxfo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW1783	M3e1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjiTWM2OD1zMUCuNlIhdk1?	M4C2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
COLO-680N	M2[5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmraTWM2OD1zMUCuO\|Yhdk1?	NYnhWlR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-N87	NW\NS21KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfINnhuUUN3ME2xNVEvODRibl2=	NUTvdGJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SK-MEL-28	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXntSXpUUUN3ME2xNVEvPTVibl2=	Mn3FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BT-20	M3yxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnSzTWM2OD1zMUKuNFEhdk1?	M2jscFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1648	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\jcWlEPTB;MUGzJI5O	NUTIXFJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
no-11	NIn5[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\kTWM2OD1zMUOuNlghdk1?	NHLUdVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MOLT-13	NX7RbGtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTFzMz60OEBvVQ>?	NH\TWYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H2170	NELxUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFzND61NUBvVQ>?	NF:3OnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HTC-C3	NEnOXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXPSokyUUN3ME2xNVYvQDVibl2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LU-99A	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfVSHNKSzVyPUGxO{4zOSCwTR?=	NGjrfIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC2998	NX7lU\|JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnUTWM2OD1zMUeuPVIhdk1?	M3K3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NB13	MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTFzNz65PUBvVQ>?	Mm\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GT3TKB	M1\pNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXe5RYpHUUN3ME2xNVgvODhibl2=	M4TqTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BT-549	NVLKemZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHizPINKSzVyPUGxPE46PSCwTR?=	Mn3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H747	MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTFzOT6zOEBvVQ>?	Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-1	NYL4VmFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\ySlNKSzVyPUGyNE4zKG6P	MmrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LB831-BLC	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXxOGJQUUN3ME2xNlAvPjNibl2=	M2n6dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NMC-G1	M3W5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF{MT6xNUBvVQ>?	NX;hc\|luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-679	NHL1[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTF{Mj6xOUBvVQ>?	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HL-60	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml76TWM2OD1zMkOuNUBvVQ>?	NXnIUpJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MKN7	NV:4O2k3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HGVWlEPTB;MUKzMlg{KG6P	M2n5fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RERF-LC-MS	NF7jS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfQTWM2OD1zMkSuN\|Ehdk1?	M1z3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
DMS-114	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTVTWM2OD1zMkWuNFkhdk1?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuP-T4	Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF{Nj65O{BvVQ>?	MlzyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC2157	M1j6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXi4PYpLUUN3ME2xNlcvPSCwTR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	NVjm[JU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTF{OD64JI5O	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCT-116	Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfzU2xTUUN3ME2xN\|AvPjRibl2=	NEDuNmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BB30-HNC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XnR2lEPTB;MUOwMlc5KG6P	Mki0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-270	NFm3dW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXnTWM2OD1zM{CuPFghdk1?	Mn;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MFM-223	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXldYVmUUN3ME2xN\|EvPTFibl2=	NWTkPZAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NH-12	M1y5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHOTWM2OD1zM{KuPVkhdk1?	MkTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
U-118-MG	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fwdmlEPTB;MUOzMlYzKG6P	M{PuZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ESS-1	NUX5OHQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7vTWM2OD1zM{WuNVghdk1?	NVvyN5FGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
D-247MG	NXT1dWxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXHTWM2OD1zM{WuNlEhdk1?	M3LL[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGROV-1	NEjOUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF\|NT63OkBvVQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
C-33-A	NV32XlE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITFZnhKSzVyPUGzOU46PyCwTR?=	NHvacVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1693	M3zETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHsdld{UUN3ME2xN\|YvOTJibl2=	M373SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MLMA	NYjRT3lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHqTWM2OD1zM{[uOVghdk1?	NFLvZpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-N-AS	NVnYcXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jEcWlEPTB;MUO3MlE4KG6P	NHuwbFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1755	MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\IRWlEPTB;MUO4Mlg2KG6P	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CHP-134	M4D4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vSXGlEPTB;MUO5MlU2KG6P	NXv5dYtORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LS-513	NGnDOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;0TWM2OD1zNECuPVEheE1?	NHXBR2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TE-12	M1X5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHDWJdmUUN3ME2xOFAvQTNibl2=	NFrUXpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KNS-42	M{LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfuT4ZKSzVyPUG0OE4{KG6P	M2L3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SJRH30	M2HrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TBfmlEPTB;MUS0MlQ1KG6P	NWrHU\|F5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H1092	M4XkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fSZWlEPTB;MUS0MlUzKG6P	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	NFjlNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPrTWM2OD1zNE[uPFEhdk1?	NHGybJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-MEL-3	M{nFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPpTWM2OD1zNEeuOVUhdk1?	NE\VUlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-N-FI	NIrF[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELFbYRKSzVyPUG0O{42QSCwTR?=	NIjVdII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H2126	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jXc2lEPTB;MUS4MlE2KG6P	M2D1VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1299	NH;aUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\rTWM2OD1zNUCuNlIhdk1?	NWL5[pNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CFPAC-1	NHHCOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGH1b2JKSzVyPUG1NE43PiCwTR?=	M3HkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H661	NIrB[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXxZpdKSzVyPUG1NU4zPiCwTR?=	NVrUc2t{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-70	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{L5fWlEPTB;MUWxMlc6KG6P	MkDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW900	NV;G[mhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jGSWlEPTB;MUW0MlY2KG6P	NU\FU29nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Ca-Ski	NHT4dm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTF3Nj6zPUBvVQ>?	MmnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HPAF-II	NGW2[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\EfXh[UUN3ME2xOVYvPDdibl2=	M1jMUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LB2518-MEL	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTF3Nz6xJI5O	NXjwfY5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LC-2-ad	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfnTGw{UUN3ME2xOVgvPjJibl2=	MlzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCC1806	M2jyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nxXWlEPTB;MU[3Mlg5KG6P	M1TEVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
UACC-62	NFTVWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHqTWx2UUN3ME2xOlgvODlibl2=	MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KM-H2	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXsTWM2OD1zN{CuOVghdk1?	NYq1bFlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2347	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\LVld1UUN3ME2xO\|IvPzJibl2=	NYPXWGk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SCC-15	NHHoR\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXtV4ZKSzVyPUG3N{43PiCwTR?=	NV;Bb5RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BB49-HNC	NV76WGVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTF5Mz64NUBvVQ>?	M{GzeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GMS-10	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF5Mz65OEBvVQ>?	NGrmR4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H2052	M3G3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPFTWM2OD1zN{SuPUBvVQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SW626	NVztOGFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrXTWM2OD1zN{[uNFYhdk1?	MlHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-415	M2fYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHpOXR3UU

研究领域

产品类型